The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.
Source：MarketWatch
友情提醒：請廣大讀者理性看待市場資訊，切實提高風險意識。站內所有內容僅系市場資訊或相關方觀點，不構成任何形式投資建議。